Literature DB >> 27858213

Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma.

Young Jin Heo1, Ji Eun Park2, Ho Sung Kim3, Ji Ye Lee2, Soo Jeong Nam4, Seung Chai Jung2, Choong Gon Choi2, Sang Joon Kim2.   

Abstract

OBJECTIVES: To determine if gemistocytic grade II astrocytoma (GemA) and its MR imaging characteristics are associated with a shorter time-to-progression (TTP) compared with non-gemistocytic grade II astrocytoma (non-GemA).
MATERIALS AND METHODS: We enrolled 78 patients who were followed up more than 5 years (29 pathologically proven GemA and 49 non-GemA) during a 10-year period. Contrast-enhanced T1-weighted, diffusion-weighted imaging (DWI), dynamic susceptibility contrast (DSC), and MR spectroscopy (MRS) and clinical data were retrospectively reviewed. Clinical and MR imaging features were analyzed as possible prognostic factors of high-grade transformation, and multivariate analysis of TTP was performed using Cox proportional modeling.
RESULTS: GemA showed more frequent high-grade features than non-GemA, including diffusion restriction (P < .001), increased choline/creatine (P = .02), and increased choline/NAA ratio (P = .015). Patients with GemA had a significantly shorter median TTP (53.1 vs 68 months; P < .001). A gemistocytic histopathology (hazard ratio = 3.42; P = .015) and low ADC (hazard ratio = 3.61; P = .001) were independently associated with a shorter TTP.
CONCLUSIONS: GemA can present with MR imaging findings mimicking high-grade glioma at initial diagnosis and transforms to high-grade disease earlier than non-GemA. Low ADC on DWI might be useful in stratifying the risk of progression in patients with grade II astrocytoma. KEY POINTS: • Gemistocytic grade II astrocytoma (GemA) showed more frequent high-grade features than non-GemA. • Patients with GemA had a significantly shorter median TTP than non-GemA. • Gemistocytic histopathology and low ADC were independently associated with shorter TTP.

Entities:  

Keywords:  Astrocytoma; Diffusion magnetic resonance imaging; Disease progression; Gemistocytic astrocytoma; Grade II

Mesh:

Year:  2016        PMID: 27858213     DOI: 10.1007/s00330-016-4649-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

1.  A gemistocytic astrocytoma demonstrated high intensity on MR images. Protein hydration layer.

Authors:  K Abe; H Hasegawa; Y Kobayashi; H Fujimura; S Yorifuji; S Bitoh
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

Review 3.  The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis.

Authors:  Qun Wang; Hui Zhang; JiaShu Zhang; Chen Wu; WeiJie Zhu; FangYe Li; XiaoLei Chen; BaiNan Xu
Journal:  Eur Radiol       Date:  2015-10-15       Impact factor: 5.315

Review 4.  Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective.

Authors:  Tarik Tihan; Poonam Vohra; Mitchel S Berger; G Evren Keles
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Authors:  Ryuji Murakami; Takeshi Sugahara; Hideo Nakamura; Toshinori Hirai; Mika Kitajima; Yoshiko Hayashida; Yuji Baba; Natsuo Oya; Jun-Ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2007-03-13       Impact factor: 11.105

Review 7.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Authors:  M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs
Journal:  Lancet Oncol       Date:  2011-04-05       Impact factor: 41.316

Review 8.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

9.  Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology.

Authors:  Ranjith Babu; Jacob H Bagley; Jong G Park; Allan H Friedman; Cory Adamson
Journal:  J Neurosurg       Date:  2013-05-10       Impact factor: 5.115

10.  Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging.

Authors:  Osamu Togao; Akio Hiwatashi; Koji Yamashita; Kazufumi Kikuchi; Jochen Keupp; Koji Yoshimoto; Daisuke Kuga; Masami Yoneyama; Satoshi O Suzuki; Toru Iwaki; Masaya Takahashi; Koji Iihara; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-03-22       Impact factor: 5.315

View more
  2 in total

Review 1.  Systematic review-Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers.

Authors:  Zabina Satar; Gary Hotton; George Samandouras
Journal:  Neurooncol Adv       Date:  2021-07-27

2.  Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.

Authors:  Satoshi Nakasu; Yoko Nakasu
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.